We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+46.89%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$351M
(+27%)
Cap. Flow
+$70.1M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
547
New
45
Increased
181
Reduced
257
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$11.8M |
| 2 |
NVIDIA
NVDA
|
+$8.71M |
| 3 |
Apple
AAPL
|
+$8.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$7.29M |
| 5 |
Marvell Technology
MRVL
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Gold Trust
IAU
|
+$8.15M |
| 2 |
SPDR Gold Trust
GLD
|
+$7.23M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$6.88M |
| 4 |
AstraZeneca
AZN
|
+$5.05M |
| 5 |
British American Tobacco
BTI
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 47.74% |
| 2 | Healthcare | 19.17% |
| 3 | Communication Services | 9.91% |
| 4 | Consumer Discretionary | 7.67% |
| 5 | Consumer Staples | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Sana Biotechnology
SANA
$913M
| $155K | 0.01% |
44,290
-2,979
| -6% | -$9.6K |
|
377
Diageo
DEO
$47.3B
| $151K | 0.01% |
1,884
| – | – |
|
378
Arbutus Biopharma
ABUS
$871M
| $151K | 0.01% |
31,438
-2,691
| -8% | -$11.8K |
|
379
Janux Therapeutics
JANX
$950M
| $149K | 0.01% |
9,706
-1,089
| -10% | -$15.8K |
|
380
Biohaven
BHVN
$2.18B
| $149K | 0.01% |
10,000
-800
| -7% | -$8.61K |
|
381
Maravai LifeSciences
MRVI
$987M
| $146K | 0.01% |
23,476
-2,501
| -10% | -$10.8K |
|
382
Replimune Group
REPL
$724M
| $145K | 0.01% |
13,141
-1,512
| -10% | -$9.25K |
|
383
Editas Medicine
EDIT
$411M
| $144K | 0.01% |
44,424
+27,101
| +156% | +$79.2K |
|
384
Omeros
OMER
$821M
| $144K | 0.01% |
15,119
-3,863
| -20% | -$46K |
|
385
Palisade Bio
PALI
$353M
| $142K | 0.01% |
+67,890
| New | +$134K |
|
386
Amphastar Pharmaceuticals
AMPH
$846M
| $142K | 0.01% |
7,017
-1,034
| -13% | -$20.9K |
|
387
Theravance Biopharma
TBPH
$874M
| $139K | 0.01% |
8,205
-787
| -9% | -$13K |
|
388
Phathom Pharmaceuticals
PHAT
$953M
| $138K | 0.01% |
12,693
-1,290
| -9% | -$14.7K |
|
|
GRFS
389
Grifois
GRFS
$5.27B
| $137K | 0.01% |
19,415
-2,234
| -10% | -$17.6K |
|
390
Zevra Therapeutics
ZVRA
$574M
| $135K | 0.01% |
9,408
-582
| -6% | -$6.47K |
|
|
COAG
391
Hemab Therapeutics
COAG
$2.35B
| $132K | 0.01% |
+3,600
| New | +$99.3K |
|
|
DBVT
392
DBV Technologies
DBVT
$823M
| $131K | 0.01% |
8,000
+3,000
| +60% | +$56.6K |
|
393
Geron
GERN
$949M
| $131K | 0.01% |
102,098
-11,183
| -10% | -$15.8K |
|
|
ESPR
394
DELISTED
Esperion Therapeutics
ESPR
| $129K | 0.01% |
40,970
-1,454
| -3% | -$4.07K |
|
|
KMTS
395
Kestra Medical Technologies
KMTS
$1.34B
| $127K | 0.01% |
5,000
+2,500
| +100% | +$52.3K |
|
396
ARS Pharmaceuticals
SPRY
$572M
| $127K | 0.01% |
15,804
-1,737
| -10% | -$14.9K |
|
397
Encompass Health
EHC
$11.3B
| $126K | 0.01% |
+1,250
| New | +$129K |
|
398
Precision BioSciences
DTIL
$187M
| $126K | 0.01% |
+16,000
| New | +$113K |
|
399
Candel Therapeutics
CADL
$730M
| $120K | 0.01% |
11,661
-1,337
| -10% | -$10.1K |
|
400
Aclaris Therapeutics
ACRS
$750M
| $118K | 0.01% |
22,228
+827
| +4% | +$3.69K |
|
Similar funds
HA
TFS
GC
PA
JPM
NRI
CPO
LCI
China Universal Asset Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, China Universal Asset Management Company held 547 positions worth $1.67B, up 27% from $1.32B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company deployed $70.1M of net new capital in Q2 2026, opening 45 new positions and adding to 181 existing holdings. Its largest new stake was Onto Innovation: 10,200 shares worth $3.86M.
By sector, the portfolio is most concentrated in Technology at 48% of assets, up from 35% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was iShares Gold Trust, an estimated $8.15M trimmed.
- China Universal Asset Management Company's largest Q2 2026 buy was Onto Innovation: 10,200 shares worth $3.86M.
- China Universal Asset Management Company added most to Amazon in Q2 2026, an estimated $11.8M increase.
- China Universal Asset Management Company's biggest Q2 2026 reduction was iShares Gold Trust, cutting an estimated $8.15M.
- China Universal Asset Management Company fully exited AstraZeneca in Q2 2026, selling an estimated $5.05M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $1.67B portfolio in Q2 2026.
- China Universal Asset Management Company opened 45 new positions and closed 36 in Q2 2026.
- China Universal Asset Management Company's portfolio value rose 27% quarter-over-quarter to $1.67B.
Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.